Establishment of endobarrier during screening esophagogastroduodenoscopy during COVID-19 pandemic

Efficacy of endobarrier for preventing aerosol transmission of esophagogastroduodenoscopy during COVID-19 pandemic: A quantitative analys - Efficacy of endobarrier for preventing aerosol transmission of esophagogastroduodenoscopy: A quantitative analys

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000042939

Enrollment

100

Registered

2021-01-10

Start date

2021-01-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients undergoing esophagogastroduodenoscopy for health check and screening

Exclusion criteria

Exclusion criteria: 1. Patients who need emergency endoscopic treatment such as gastrointestinal bleeding 2. Patients with psychiatric diseases or psychiatric symptoms who are judged to have difficulty in conducting this clinical trial 3. Patients who the doctor in charge deems inappropriate

Design outcomes

Primary

Measure	Time frame
To evaluate the change of aerosol particle number before, during, and after endoscopic examination with an Endo barrier	—

Secondary

Measure	Time frame
To evaluate the change of adenosine triphosphate (ATP) bioluminescence assay before, and after endoscopy in the endoscopy unit.	—

Countries

Japan

Contacts

Public ContactHideki Kobara

Kagawa University, Faculty of Medicine Department of Gastroenterology and Neurology

kobara@med.kagawa-u.ac.jp0878912156

Outcome results